Search

Glaukos Corp

Cerrado

SectorSanidad

167.8 1.52

Resumen

Variación precio

24h

Actual

Mínimo

163.52

Máximo

168.18

Métricas clave

By Trading Economics

Ingresos

1.4M

-18M

Ventas

35M

186M

BPA

-0.14

Margen de beneficios

-9.901

Empleados

1,094

EBITDA

-333K

-5.6M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+19.39% upside

Dividendos

By Acuity

Próximas Ganancias

28 oct 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.1B

10B

Apertura anterior

166.28

Cierre anterior

167.8

Glaukos Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 oct 2026, 20:07 UTC

Glaukos Corp shares are declining, following a volatile intraday pattern, closing lower from Monday's close despite briefly recovering earlier in the session.

9 oct 2026, 20:06 UTC

News
Event

Glaukos reports positive Phase 4 trial results for iDose TR therapy, showing a significant reduction in intraocular pressure alongside cataract surgery, confirming safety.

8 oct 2026, 22:55 UTC

Glaukos Corp shares declined in after-market hours, continuing a downward trend from Thursday's close and remaining below its 20-day moving average.

7 oct 2026, 20:00 UTC

Glaukos Corp is advancing significantly with unusually high trading volume, marking a departure from recent higher daily closes since Tuesday.

6 oct 2026, 20:07 UTC

Glaukos Corp shares are declining, trading below their 20-day moving average and near the lower end of their one-month range after earlier volatility.

1 oct 2026, 20:07 UTC

Glaukos Corp's shares are declining, positioned near the lower end of their one-month range, after a brief spike earlier in the session.

30 sept 2026, 20:07 UTC

Glaukos Corp shares are advancing, rebounding from an earlier pullback, amid a broader market trend of significant gains on Wednesday.

29 sept 2026, 23:55 UTC

Glaukos Corp is trading modestly higher in after-market hours, despite fluctuations during the session, and remains below its 20-day moving average.

28 sept 2026, 20:07 UTC

Glaukos Corp is gaining ground in today's trading session, reflecting upward momentum since Friday, despite earlier pulling back from a session high.

25 sept 2026, 20:07 UTC

Glaukos Corp shares fell sharply, closing just below Thursday's close and approximately 9.45% below their 20-day moving average.

23 sept 2026, 20:01 UTC

News

Glaukos Corporation launched a keratoconus awareness campaign with Stephen Curry, but shares fell sharply today, continuing a trend of three consecutive daily declines.

22 sept 2026, 23:01 UTC

Glaukos Corp is advancing in after-market trading, reflecting a directional move since Tuesday's close, though it remains 6.99% below its 20-day moving average.

21 sept 2026, 20:06 UTC

Glaukos Corp's shares are declining, remaining below their 20-day moving average and near the lower end of their one-month range despite an earlier session recovery.

18 sept 2026, 20:02 UTC

Glaukos Corp is advancing during market hours on Friday, continuing its upward trend since Thursday's close, despite lower trading compared to earlier sessions.

17 sept 2026, 19:36 UTC

Glaukos Corp shares fell sharply, currently at their lowest point of the day and significantly below the 20-day moving average.

16 sept 2026, 19:03 UTC

Glaukos Corp shares fell sharply, reversing a trend of higher daily closes, amid unusually high market volume on Wednesday.

14 sept 2026, 19:16 UTC

Glaukos Corp shares are higher today, despite no specific news, following three consecutive sessions of declines. The stock remains below its 20-day moving average.

11 sept 2026, 20:08 UTC

Glaukos Corp shares are lower today, continuing a decline over the past four sessions and trading below the 20-day moving average.

10 sept 2026, 20:03 UTC

Glaukos Corp shares are lower today, breaking a trend of higher closes. The stock is trading with unusually high volume amid no specific news.

8 sept 2026, 20:07 UTC

Glaukos Corp shares are higher today, recovering from an early dip amid speculation of a potential interest rate hike following a strong jobs report.

1 sept 2026, 19:31 UTC

Glaukos Corp. shares are lower today amid broader market volatility and rising U.S. Treasury yields, continuing a three-session decline.

31 ago 2026, 20:07 UTC

Glaukos Corp shares are lower amid broader market concerns over inflation and potential Fed rate hikes. Earlier, the stock rebounded from a session low.

28 ago 2026, 20:07 UTC

Glaukos Corp shares are lower during Friday's session amid rising U.S. Treasury yields and broader market trends, with no specific company news identified.

27 ago 2026, 20:07 UTC

Glaukos Corp. shares are higher amid broader market trends. A decline in initial jobless claims may support a positive outlook for health care stocks.

25 ago 2026, 20:07 UTC

Glaukos Corp shares are lower today amid broader market declines, despite remaining above their 20-day moving average and near the top of their one-month range.

21 ago 2026, 19:56 UTC

Glaukos Corp's shares are higher today, reflecting a cumulative gain since Thursday. The stock remains near the upper end of its one-month range.

20 ago 2026, 20:06 UTC

Glaukos Corp. shares are lower today, reflecting a decline from Wednesday's close. The stock earlier pulled back after reaching a session high.

19 ago 2026, 20:06 UTC

News

Glaukos Corp will present at the Wells Fargo Healthcare Conference on September 9, 2026, as shares gain during Wednesday's trading session.

14 ago 2026, 19:46 UTC

Glaukos Corp. shares are lower today, reaching a session low amid broader market declines following a surprise drop in U.S. retail sales for July.

13 ago 2026, 19:22 UTC

Glaukos Corp. shares are higher today amid unusually high trading volume. The stock remains significantly above its 20-day moving average.

Comparación entre iguales

Cambio de precio

Glaukos Corp previsión

Precio Objetivo

By TipRanks

19.39% repunte

Estimación a 12 Meses

Media 197.583 USD  19.39%

Máximo 225 USD

Mínimo 172 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Glaukos Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

12

Comprar

1

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat